Top

Published in:

01-09-2015 | Research Article

Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer

Authors: Wei Peng, Guoqiu Wu, Hong Fan, Jianzhong Wu, Jifeng Feng

Published in: Tumor Biology | Issue 9/2015

Abstract

Gastric cancer (GC) is the second common cause of cancer-related death worldwide. Long noncoding RNAs (lncRNAs) are emerging as novel regulators in the cancer paradigm. However, investigation of lncRNAs on GC is still in its infancy. In this study, we focused on lncRNA SPRY4 intronic transcript 1 (SPRY4-IT1) and investigated its expression pattern, clinical significance, biological function, and molecular mechanism in GC. SPRY4-IT1 expression was examined, and its correlation with clinicopathological characteristics and patient prognosis was analyzed. A series of assays were performed to understand the role of SPRY4-IT1 in GC. SPRY4-IT1 expression was elevated in GC tissues and cell lines, and SPRY4-IT1 levels were highly positively correlated with tumor size, invasion depth, distant metastasis, TNM stage, and reduced overall survival (OS) and disease-free survival (DFS). A multivariate analysis showed that SPRY4-IT1 expression is an independent prognostic factor of OS and DFS in patients with GC. Additionally, the results of in vitro assays showed that the suppression of SPRY4-IT1 expression in GC cell line MKN-45 significantly reduced cell proliferation, colony formation, and cell migration/invasion. Moreover, the tumorigenic effects of SPRY4-IT1 were partially mediated by the regulation of certain cyclins and matrix metalloproteinases (MMPs)-related genes. Our data suggest that SPRY4-IT1 plays a critical role in GC tumorigenesis and may represent a novel prognostic marker and potential therapeutic target in patients with GC.

Hartgrink HH, Jansen EPM, van Grieken NCT, van de Velde CJH. Gastric cancer. Lancet. 2009;374(9688):477–90. doi:10.1016/s0140–6736(09)60617–6.CrossRefPubMedPubMedCentral

Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer a meta-analysis. Jama–J Am Med Assoc. 2010;303(17):1729–37. doi:10.1001/jama.2010.534.CrossRef

Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci. 2010;14(4):302–8.PubMed

Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41. doi:10.1016/j.cell.2009.02.006.CrossRefPubMed

Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–504. doi:10.1101/gad.1800909.CrossRefPubMedPubMedCentral

Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21(6):354–61. doi:10.1016/j.tcb.2011.04.001.CrossRefPubMed

Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb–dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71(20):6320–6. doi:10.1158/0008-5472.can-11-1021.CrossRefPubMed

Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–9. doi:10.1158/0008-5472.can-12-2850.CrossRefPubMed

Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132(1):330–42. doi:10.1053/j.gastro.2006.08.026.CrossRefPubMed

10.

Peng W, Gao W, Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol. 2014;31(12):1–7.CrossRef

11.

Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The melanoma–upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011;71(11):3852–62. doi:10.1158/0008-5472.can-10-4460.CrossRefPubMed

12.

Xie HW, Wu QQ, Zhu B, Chen FJ, Ji L, Li SQ, et al. Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumor Biol. 2014;35(8):7743–54. doi:10.1007/s13277-014-2013-y.CrossRef

13.

Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, et al. EZH2–mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial–mesenchymal transition. Cell Death Dis. 2014;5:e1298. doi:10.1038/cddis.2014.256.CrossRefPubMedPubMedCentral

14.

Zou YF, Jiang ZY, Yu X, Sun M, Zhang YY, Zuo Q, et al. Upregulation of long noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR–8SV/neo. PLos One. 2013;8(11):e79598. doi:10.1371/journal.pone.0079598.CrossRefPubMedPubMedCentral

15.

Wang X, Yu HG, Lu XY, Zhang P, Wang ML, Hu YK. miR–22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. Biochem Biophys Res Commun. 2014;445(1):175–9. doi:10.1016/j.bbrc.2014.01.160.CrossRefPubMed

16.

Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362(9380):305–15. doi:10.1016/s0140-6736(03)13975-x.CrossRefPubMed

17.

Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 2011;71(1):3–7. doi:10.1158/0008-5472.can-10-2483.CrossRefPubMedPubMedCentral

18.

Maruyama R, Suzuki H. Long noncoding RNA involvement in cancer. BMB Rep. 2012;45(11):604–11. doi:10.5483/BMBRep.2012.45.11.227.CrossRefPubMedPubMedCentral

19.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.CrossRefPubMed

20.

Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther. 2002;1(3):226–31.CrossRefPubMed

21.

Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 2003;15(2):158–63. doi:10.1016/s0955–0674(03)00008–5.CrossRefPubMed

22.

Overall CM, Lopez–Otin C. Strategies for MMP inhibition in cancer: innovations for the post–trial era. Nat Rev Cancer. 2002;2(9):657–72. doi:10.1038/nrc884.CrossRefPubMed

23.

Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont E. The possible role of matrix metalloproteinase (MMP)–2 and MMP–9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 2004;50(2):87–100. doi:10.1016/j.critevonc.2003.09.001.CrossRefPubMed

Title: Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer
Authors: Wei Peng
Guoqiu Wu
Hong Fan
Jianzhong Wu
Jifeng Feng
Publication date: 01-09-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3376-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2015

Retraction Note to: A comprehensive analysis of candidate genes and pathways in pancreatic cancer

Survivin splice variants and their diagnostic significance

Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study

K-Ras promotes the non-small lung cancer cells survival by cooperating with sirtuin 1 and p27 under ROS stimulation

Retraction Note to: Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset

ObRb downregulation increases breast cancer cell sensitivity to tamoxifen

Keynote webinar | Spotlight on antibody–drug conjugates in cancer